

Benchmarking of Budget Impact Results: An Updated Systematic Review of US Budget Impact Analyses

Liu R¹, Botteman M²

¹OPEN Health, Bethesda, MD, USA; ²Formerly of OPEN Health, Bethesda, MD, USA

Abstract ID: 126363



OPEN HEALTH

INTRODUCTION

- To inform drug formulary decision-making, US reimbursement authorities (e.g., US healthcare plans) commonly require budget impact analyses (BIAs) to estimate the financial impact of certain treatments among a target population after a new healthcare technology is adopted
- Results of BIAs from a US payer perspective are typically reported as budget impact (BI) per member per month (PMPM)
- However, unlike with cost-effectiveness analyses, which often rely on the use of established thresholds (e.g., \$100,000 to \$150,000/QALY gained in the US) to define what is an acceptable cost-effectiveness ratio, proper interpretation of BI PMPM is hampered by the lack of accepted pre-specified PMPM thresholds defining what is a financially acceptable BI
- As a result, author-provided interpretations regarding BIA acceptability could be misleading
- In this context, we updated a prior systematic review of published US BIAs¹ to establish PMPM benchmarks and assess how BIA authors qualitatively interpreted their own results

OBJECTIVES

- To update a previous systematic review of full-text, peer-reviewed BIAs for pharmacotherapy from a US payer perspective to establish BI PMPM benchmarks
- To assess the association between BI PMPM and authors' interpretation

METHODS


- Systematic PubMed/Embase searches (01/2003-3/2023) were conducted to identify full-text, peer-reviewed BIAs that reported BI PMPM associated with pharmacotherapies from a US payer perspective
- The key outcomes measure was the cumulative distribution of BI PMPM estimates
- Association between a BI PMPM reported by authors and these authors' interpretations were analyzed descriptively
- All BI PMPM estimates were inflation-adjusted to 2022 US dollars

RESULTS

- Of the 92 identified BIAs, 48 (52%) were published in or after 2018 (Fig.1)

RESULTS (cont'd)


Figure 1. Median BI PMPM (€) by Year of Publication (N=92)



BI, budget impact; PMPM, per member per month
No study published in 2004 was identified


- Of the 92 base case BI PMPM, the median (interquartile range [IQR]) was €1.4 (€-0.2, €4.4) (Fig.2)
- Of the 92 BI PMPM, 66 (72%) reported BI PMPM >€0, among which the median (IQR) was €2.2 (€1.3, €7.1) (Fig.3)

Figure 2. Cumulative Distribution of BI PMPM (€, N=92)



BI, budget impact; IQR, interquartile range; PMPM, per member per month


Figure 3. Cumulative Distribution of BI PMPM Among PMPM >€0 (N=66)



BI, budget impact; IQR, interquartile range; PMPM, per member per month

- Of the 66 BI PMPM >€0, 56 (84.8%) had interpretations by their authors
- Among the most common terms used to describe financial acceptability for PMPM >€0, interpretation patterns by quartile (ordered here from lowest to highest) were ambiguous (“minimal”: 29%/25%/12%/12%; “small”: 29%/31%/19%/0%; “modest”: 12%/19%/31%/18%) (Fig. 4)
- On the other hand, interpretations appeared to be more frequently provided for lower versus higher PMPM quartiles: Q1 (i.e., lowest quartile), 100%; Q4 (i.e., highest quartile), 71% (Fig.4)

Figure 4. Interpretation by BI PMPM Quartile Among PMPM >€0 (N=66)




BI, budget impact; IQR, interquartile range; PMPM, per member per month

RESULTS (cont'd)

- When analyzed by interpretation term, the median PMPM was lowest for “minimal” (€1.4), followed by “limited/etc.” (€1.6), “small” (€1.5), “moderate/etc.” (€3.6), “modest” (€4.9), no interpretation (€6.6), and “considerable/etc.” (€347.0) (Fig.5)

Figure 5. Median BI PMPM (€) by Interpretation Among PMPM >€0 (N=66)



BI, budget impact; PMPM, per member per month

CONCLUSIONS

- We provide updated benchmarks for BI PMPM for US BIAs
- Additional research is needed to establish benchmarks to guide BI interpretation that account for other factors like therapeutic area, disease burden, and disease rarity
- Authors might want to refrain from providing potentially misleading qualitative judgments regarding BI acceptability

ACKNOWLEDGEMENTS

- The authors thank Zhaoli Tang and Christina DuVernay, employees of OPEN Health, for editorial assistance with the poster.

REFERENCE

- Waldeck, M., Liu, R., Kumar, V.M. and Botteman, M., 2019. PNS54 SYSTEMATIC REVIEW AND BENCHMARKING OF US BUDGET IMPACT ANALYSES. Value in Health, 22, p.S295.